One such immune cell is the resident lymph node subcapsular sinus (SCS) CD169+ macrophage, which has been linked to a better patient prognosis when present in regional lymph nodes and LNM of various solid tumors [15–20], including tumor draining lymph nodes and LNM from breast cancer patients [21–24]. This evidence concerns the gene SIGLEC1 and breast cancer.